MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome
Read the press release
MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
Read the press release
MavriX Bio Receives FDA Fast Track Designation for MVX-220 for Treatment of Angelman Syndrome
Read the press release
MavriX Bio MVX-220 Update
MavriX Bio’s gene therapy MVX-220 receives FDA Fast Track designation, with its Phase 1/2 ASCEND-AS trial now listed and a community webinar set for October 9.
MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome
The FDA has cleared MavriX Bio’s IND application for MVX-220, an investigational AAV gene therapy for Angelman syndrome.
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome
FAST launches MavriX Bio and CourageAS Bio, two new biotech companies advancing gene replacement and gene-editing therapies for Angelman syndrome under its AS²Bio accelerator.
Jim Wilson move from UPENN to Biotech and what this means for Angelman syndrome.
“This is a great decision by Dr. Wilson and that of The University of Pennsylvania to get the development of these gene therapies out of academia and into a well-resourced biotech environment that can execute more efficiently. This is exciting news for rare disease and for other companies that can now leverage the expertise of […]
To Further Advance Gene Therapy Research, Industry Pioneer Jim Wilson is Forming Two Independent Companies Dedicated to Genetic Medicine
Read the press release
FAST to Advance Gene Therapy Candidate through IND-Enabling Studies Conducted in Partnership with the University of Pennsylvania
The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome (AS). Angelman syndrome is a rare neurogenetic disorder that is estimated to impact approximately […]